ESC TV Today – Your Cardiovascular News

In this engaging discussion, cardiology specialist Stephanie Schwarting, affiliated with renowned institutions in Munich and Heidelberg, shares her expertise on arrhythmias within cardiac amyloidosis. She delves into the complexities of rate control influenced by heart rate dependence and autonomic dysfunction. The conversation covers the challenges of ablation based on disease stage and the unpredictable progression of conduction disease. Schwarting also emphasizes the importance of individualized monitoring strategies and the role of multidisciplinary teams in enhancing patient care.

Stephanie Schwarting, a cardiac amyloidosis expert from University Hospital Munich, dives into arrhythmias in transthyretin cardiac amyloidosis, discussing management strategies and the nuances of treating atrial fibrillation in this context. Ahmad Masri, a cardiologist specializing in hypertrophic cardiomyopathy from Oregon Health & Science University, explores the complexities of managing LVOT obstruction and the role of myosin inhibitors versus traditional therapies. Both guests provide invaluable insights into cutting-edge treatments and patient management approaches.

Join cardiologist Milton Packer as he dives into the critical role of visceral adiposity in managing heart failure with preserved ejection fraction (HFpEF). He explores how SGLT2 inhibitors and GLP-1 agonists shift adipose biology towards a protective state, challenging traditional views. The integration of artificial intelligence in echocardiography systems is also discussed, highlighting its potential for early disease detection and the importance of training on diverse populations to avoid bias. Packer's insights signal a pivotal shift in cardiovascular treatment strategies.

Host: Susanna Price Guest: Rudolf de Boer Want to watch that extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this engaging discussion, Professor Robert Storey, a renowned cardiologist and director at the University of Sheffield, shares his expertise on chronic coronary syndromes. He dives into the effectiveness of anti-anginal medications and how lifestyle changes can dramatically relieve symptoms. The conversation also covers the benefits of PCI in reducing medication needs and the complexities of beta blocker side effects. Robert emphasizes the importance of careful management in antithrombotic therapy, highlighting when it's appropriate to consider stopping these treatments.

Dive into recent cardiology insights as experts discuss fulminant myocarditis outcomes and the surprising benefits of beta blockers in heart failure with COPD. Explore innovative TAVI strategies for bicuspid aortic stenosis and the importance of specialized heart valve centers. Learn about the shift in TAVI age recommendations and effective management of mitral regurgitation. Plus, uncover the latest in anti-anginal drugs and the intriguing question: does wearing a white coat really enhance intelligence?

In this engaging discussion, Tim Chico, a renowned Professor of Cardiovascular Medicine, dives into the fascinating world of smartwatches and their role in heart health. He sheds light on how these devices detect atrial fibrillation and arrhythmias through advanced technologies like photoplethysmography. Chico also addresses the challenges of integrating smartwatch data into healthcare, emphasizing the need for better accessibility and accuracy. Expect insights on the future of health data and how it could revolutionize personalized medicine.

Carlos Aguiar, a cardiology expert, shares valuable insights on cutting-edge cardiovascular research. They discuss oral anticoagulation strategies in atrial fibrillation, emphasizing the CHADS-VASc score and innovative surgical options. The role of smartwatches in detecting AFib is also highlighted, exploring their accuracy and challenges in interpretation. Additionally, they reflect on the Lyon Diet Heart Study and its groundbreaking findings on the Mediterranean diet's positive influence on heart health, reshaping dietary perspectives in cardiology.

Host: Emer Joyce Guest: Christian Hassager Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1812?resource=interview  Want to watch the full episode? Go to: https://esc365.escardio.org/event/1812   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Carlos Aguiar, a cardiology expert known for his role on Cardiology This Week, dives into the complexities of atrial fibrillation and heart failure. He discusses how these conditions interact and the implications for patient management. The conversation shifts to the critical issue of temperature management after cardiac arrest, evaluating different cooling methods and their effectiveness. Aguiar also sheds light on the intriguing concept of collider bias in cardiovascular research, emphasizing its importance in deriving accurate findings.